News

  • 19 February 2018

    Wilson enrols first patient in Phase III trial of WTX101

    Wilson Therapeutics has enrolled the first patient in the FOCuS Phase III trial to evaluate WTX101 (bis-choline tetrathiomolybdate) in comparison with standard of care (SoC) for treatment of Wilson disease.

  • 16 February 2018

    Prostate cancer drug given approval by the FDA

    The US Food and Drug Administration (FDA) has approved Johnson & Johnson’s (J&J) next-generation prostate cancer drug apalutamide, to be sold under the brand name Erleada.

  • 16 February 2018

    Citius enrols first patient in Phase III trial of Mino-Lok

    Citius Pharmaceuticals has enrolled the first patient in a Phase III clinical trial evaluating the efficacy and safety of Mino-Loktherapy in combination with systemic antibiotics in the treatment of catheter-related...